Mostrar el registro sencillo

dc.contributor.authorTeruel, María
dc.contributor.authorMartín, José Ezequiel
dc.contributor.authorGonzález Juanatey, Carlos
dc.contributor.authorLópez Mejías, Raquel
dc.contributor.authorMiranda Filloy, José Alberto
dc.contributor.authorBlanco Alonso, Ricardo 
dc.contributor.authorBalsa Criado, Alejandro
dc.contributor.authorPascual Salcedo, Dora
dc.contributor.authorRodríguez Rodríguez, Luis
dc.contributor.authorFernández Gutiérrez, Benjamín
dc.contributor.authorOrtiz, Ana M.
dc.contributor.authorGonzález Álvaro, Isidoro
dc.contributor.authorGómez Vaquero, Carmen
dc.contributor.authorBottini, Nunzio
dc.contributor.authorLlorca Díaz, Javier
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel 
dc.contributor.authorMartín Ibáñez, Javier
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2012-05-10T08:05:37Z
dc.date.available2012-05-10T08:05:37Z
dc.date.issued2011-07-18
dc.identifier.issn1478-6354
dc.identifier.urihttp://hdl.handle.net/10902/534
dc.description.abstractIntroduction Acid phosphatase locus 1 (ACP1) encodes a low molecular weight phosphotyrosine phosphatase implicated in a number of different biological functions in the cell. The aim of this study was to determine the contribution of ACP1 polymorphisms to susceptibility to rheumatoid arthritis (RA), as well as the potential contribution of these polymorphisms to the increased risk of cardiovascular disease (CV) observed in RA patients. Methods A set of 1,603 Spanish RA patients and 1,877 healthy controls were included in the study. Information related to the presence/absence of CV events was obtained from 1,284 of these participants. All individuals were genotyped for four ACP1 single-nucleotide polymorphisms (SNPs), rs10167992, rs11553742, rs7576247, and rs3828329, using a predesigned TaqMan SNP genotyping assay. Classical ACP1 alleles (*A, *B and *C) were imputed with SNP data. Results No association between ACP1 gene polymorphisms and susceptibility to RA was observed. However, when RA patients were stratified according to the presence or absence of CV events, an association between rs11553742*T and CV events was found (P = 0.012, odds ratio (OR) = 2.62 (1.24 to 5.53)). Likewise, the ACP1*C allele showed evidence of association with CV events in patients with RA (P = 0.024, OR = 2.43). Conclusions Our data show that the ACP1*C allele influences the risk of CV events in patients with RA.es_ES
dc.description.sponsorshipWe thank Sofía Vargas, Sonia Rodríguez and Rodrigo Ochoa for their excellent technical assistance, and Mercedes García Bermudez for her comments in the analysis of CV events. We thank Banco Nacional de ADN (University of Salamanca, Spain), which supplied part of the control DNA samples, and we thank all patients and donors for their collaboration. This work was supported by two grants from Fondo de Investigaciones Sanitarias PI06-0024 and PS09/00748 (Spain) and by the RETICS Program, RD08/0075 (RIER) from the Instituto de Salud Carlos III (ISCIII), within the VI PN de I+D+i 2008-2011 (FEDER). MT was supported by the Spanish Ministry of Science through the program Juan de la Cierva (JCI-2010-08227).
dc.format.extent6 p.es_ES
dc.language.isoenges_ES
dc.publisherBioMed Centrales_ES
dc.rightsAttribution 4.0 International. © 2011 Teruel et al.; licensee BioMed Central Ltd.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArthritis Research & Therapy, 2011, 13:R116es_ES
dc.titleAssociation of acid phosphatase locus 1*C allele with the risk of cardiovascular events in rheumatoid arthritis patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1186/ar3401
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 International. © 2011 Teruel et al.; licensee BioMed Central Ltd.Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International. © 2011 Teruel et al.; licensee BioMed Central Ltd.